TY - JOUR
T1 - Advances in mechanisms of resistance to aromatase inhibitors
AU - Chumsri, Saranya
AU - Schech, Amanda
AU - Chakkabat, Chakkapong
AU - Sabnis, Gauri
AU - Brodie, Angela
N1 - Funding Information:
S Chumsri has received research funding from Novartis, GlaxoSmithKline and Merck. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
PY - 2014/4
Y1 - 2014/4
N2 - Clinically, there are two distinct types of aromatase inhibitor (AI) resistance, namely acquired and innate resistance. Because the underlying mechanisms of these two types of resistance may not be mutually exclusive, strategies to tackle these resistances may not be effective when used interchangeably. Activation of growth factor receptor pathways is the hallmark of acquired AI resistance. These pathways can be targeted either at the cell surface receptor level or their downstream signaling cascades. Currently, everolimus in combination with exemestane represents a new standard of care for patients progressing on non-steroidal AIs. HDAC inhibitors have also shown promising results For innate resistance, the combination of fulvestrant and AI in the front line setting represents a new treatment option, particularly for patients who present with de novo metastatic disease. A Phase III trial is currently ongoing to evaluate the benefit of CDK 4/6 inhibitor, palbociclib, in the first line setting in combination with AI.
AB - Clinically, there are two distinct types of aromatase inhibitor (AI) resistance, namely acquired and innate resistance. Because the underlying mechanisms of these two types of resistance may not be mutually exclusive, strategies to tackle these resistances may not be effective when used interchangeably. Activation of growth factor receptor pathways is the hallmark of acquired AI resistance. These pathways can be targeted either at the cell surface receptor level or their downstream signaling cascades. Currently, everolimus in combination with exemestane represents a new standard of care for patients progressing on non-steroidal AIs. HDAC inhibitors have also shown promising results For innate resistance, the combination of fulvestrant and AI in the front line setting represents a new treatment option, particularly for patients who present with de novo metastatic disease. A Phase III trial is currently ongoing to evaluate the benefit of CDK 4/6 inhibitor, palbociclib, in the first line setting in combination with AI.
KW - CDK4/6 inhibitor
KW - HER2
KW - aromatase inhibitors
KW - breast cancer
KW - everolimus
KW - fulvestrant
KW - growth factor receptor pathways
KW - mTOR inhibitors
KW - resistance to aromatase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84896945490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896945490&partnerID=8YFLogxK
U2 - 10.1586/14737140.2014.882233
DO - 10.1586/14737140.2014.882233
M3 - Review article
C2 - 24559291
AN - SCOPUS:84896945490
SN - 1473-7140
VL - 14
SP - 381
EP - 393
JO - Expert review of anticancer therapy
JF - Expert review of anticancer therapy
IS - 4
ER -